1. Home
  2. SAM vs CELC Comparison

SAM vs CELC Comparison

Compare SAM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

HOLD

Current Price

$233.13

Market Cap

2.6B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$115.05

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAM
CELC
Founded
1984
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
3.1B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
SAM
CELC
Price
$233.13
$115.05
Analyst Decision
Hold
Strong Buy
Analyst Count
9
8
Target Price
$229.50
$100.13
AVG Volume (30 Days)
146.7K
528.5K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
95.45
N/A
EPS
9.89
N/A
Revenue
$1,964,994,000.00
N/A
Revenue This Year
$1.22
N/A
Revenue Next Year
$1.46
N/A
P/E Ratio
$23.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$186.72
$7.58
52 Week High
$260.00
$120.32

Technical Indicators

Market Signals
Indicator
SAM
CELC
Relative Strength Index (RSI) 54.72 62.68
Support Level $210.53 $97.75
Resistance Level $252.10 $120.32
Average True Range (ATR) 10.25 5.25
MACD -0.88 0.85
Stochastic Oscillator 60.20 87.20

Price Performance

Historical Comparison
SAM
CELC

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: